CK effective over the long-term

Article

Conductive keratoplasty (CK) is an effective long-term treatment for near-plano presbyopia.

Conductive keratoplasty (CK) is an effective long-term treatment for near-plano presbyopia, according to the results of a study published in the November issue of the Journal of Refractive Surgery.

Jason Stahl, MD from Kansas University Medical Center, Kansas, US evaluated the outcomes of 10 patients treated with unilateral CK, performed using the ViewPoint CK system (Refractec). Nine patients were available for follow-up at three years.

Preoperatively, the average manifest refraction spherical equivalent (MRSE) was -0.17 D and average near uncorrected visual acuity (UCVA) was J10. At three years follow-up, the mean MRSE had decreased to -1.06 D, representing a 0.25 D change from the average MRSE of -1.31 D at one year follow-up. Furthermore, at three years, all subjects had maintained an uncorrected binocular distance visual acuity of 20/20 and near UCVA averaged J3 or better in 78% of subjects.

Dr Stahl concluded that CK can be an effective long-term treatment for presbyopia.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.